NAVINFLUOR - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | NAVINFLUOR | Market Cap | 36,498 Cr. | Current Price | 7,120 ₹ | High / Low | 7,229 ₹ |
| Stock P/E | 74.1 | Book Value | 715 ₹ | Dividend Yield | 0.21 % | ROCE | 21.3 % |
| ROE | 16.0 % | Face Value | 2.00 ₹ | DMA 50 | 6,605 ₹ | DMA 200 | 5,859 ₹ |
| Chg in FII Hold | 0.04 % | Chg in DII Hold | -0.48 % | PAT Qtr | 127 Cr. | PAT Prev Qtr | 120 Cr. |
| RSI | 66.0 | MACD | 180 | Volume | 2,37,991 | Avg Vol 1Wk | 1,66,546 |
| Low price | 4,212 ₹ | High price | 7,229 ₹ | PEG Ratio | 4.25 | Debt to equity | 0.03 |
| 52w Index | 96.4 % | Qtr Profit Var | 65.2 % | EPS | 95.2 ₹ | Industry PE | 29.0 |
📊 Financials: The company shows moderate profitability with ROE at 16.0% and ROCE at 21.3%, reflecting decent efficiency in capital usage. Debt-to-equity is very low at 0.03, indicating a nearly debt-free balance sheet. Quarterly PAT rose from ₹120 Cr. to ₹127 Cr., showing stable earnings momentum. EPS of ₹95.2 supports cash flow generation, though modest relative to valuation.
💹 Valuation: Current P/E of 74.1 is significantly higher than the industry average of 29.0, suggesting overvaluation. The PEG ratio of 4.25 indicates growth prospects are limited relative to price. Book value of ₹715 against a market price of ₹7,120 implies a stretched P/B ratio. Intrinsic value appears lower than current levels, requiring caution.
🏭 Business Model: The company operates in specialty chemicals and fluorochemicals, benefiting from strong demand in pharmaceuticals, agrochemicals, and global industrial applications. Competitive advantage lies in niche product offerings, R&D capabilities, and export opportunities, though valuations remain stretched.
📈 Entry Zone: A favorable entry would be closer to ₹6,600–6,800, near the 50 DMA of ₹6,605. Current price of ₹7,120 is above fair value, so accumulation on dips is recommended.
⏳ Long-Term Holding: Strong fundamentals, niche positioning, and global demand support long-term holding. However, stretched valuations and modest growth prospects suggest cautious accumulation rather than aggressive buying.
Positive
- ✅ Strong ROCE (21.3%) and ROE (16.0%)
- ✅ Debt-free balance sheet (Debt-to-equity 0.03)
- ✅ EPS of ₹95.2 supports cash flow generation
- ✅ PAT growth from ₹120 Cr. to ₹127 Cr. shows operational resilience
Limitation
- ⚠️ Very high P/E (74.1) compared to industry average
- ⚠️ Stretched P/B ratio (Price ₹7,120 vs. Book Value ₹715)
- ⚠️ PEG ratio of 4.25 indicates limited growth prospects
Company Negative News
- 📉 Decline in DII holding (-0.48%) shows reduced domestic institutional confidence
Company Positive News
- 📈 Increase in FII holding (+0.04%) reflects foreign investor interest
- 📈 PAT growth supports earnings outlook
Industry
- 🧪 Specialty chemicals sector benefits from global demand
- 📊 Industry P/E at 29.0 suggests peers are valued lower
- 🌍 Growth opportunities in pharmaceuticals, agrochemicals, and exports
Conclusion
Overall, the company is financially stable with strong return ratios, niche positioning, and global demand. However, valuations are stretched compared to peers, and growth prospects appear limited. Best strategy is cautious accumulation near ₹6,600–6,800 for long-term holding, while avoiding aggressive buying at current levels.
Would you like me to extend this with a peer comparison against other specialty chemical companies, or a technical analysis view to highlight support/resistance and momentum indicators?